Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Shares Outstanding (Weighted Average) (2022 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Shares Outstanding (Weighted Average) data on record, last reported at $4.0 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 459.7% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.0 million, up 459.7%, while the annual FY2025 figure was $975985.0, 156.13% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $4.0 million in Q4 2025 per INM's latest filing, roughly flat from $4.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $4.0 million in Q3 2025 and bottomed at $166410.0 in Q3 2023.
  • Average Shares Outstanding (Weighted Average) over 5 years is $1.2 million, with a median of $620127.0 recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): plummeted 84.44% in 2024, then soared 537.7% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $516933.0 in 2021, then surged by 67.45% to $865619.0 in 2022, then plummeted by 53.94% to $398673.0 in 2023, then skyrocketed by 77.22% to $706546.0 in 2024, then soared by 459.7% to $4.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $4.0 million in Q4 2025, $4.0 million in Q3 2025, and $975985.0 in Q2 2025.